Thiazolidinediones - Tools for the research of metabolic syndrome X

Physiological Research

Volumn 47, Issue 4, 1998, Pages 215-225

  Komers, R ^a   Vrana A ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Hypertension; Insulin resistance; Non insulin dependent diabetes mellitus; Thiazolidinediones; Troglitazone

Indexed keywords

CIGLITAZONE; TROGLITAZONE;

ANTIOXIDANT ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; ENZYME ACTIVATION; GLUCOSE METABOLISM; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; REVIEW; SYNDROME X;

ANTIOXIDANTS; BLOOD VESSELS; CHROMANS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MICROVASCULAR ANGINA; THIAZOLES; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 0031698177     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. ANTONUCCI T., WHITCOMB R., McLAIN R., LOCKWOOD D.: Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 20: 188-193, 1997.
2. BARBAGALLO M., SHAN J., PANG P.K.T., RESNICK L.M.: Glucose-induced alterations of cytosolic free calcium in cultured rat tail artery vascular smooth muscle cells. J. Clin. Invest. 95: 763-767, 1995.
3. BERKOWITZ K., PETERS R., KJOS S.L., GOICO J., MARROQUIN A., DUNN M.E., XIANG A., AZEN S., BUCHANAN T.A.: Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 45: 1572-1579, 1996.
4. BONINI J.A., COLCA J.R., DAILEY C., WHITE M., HOFMANN C.: Compensatory alterations for insulin signal transduction and glucose transport in insulin-resistant diabetes. Am. J. Physiol. 269: E759-E765, 1995.
5. BRAISSNT O., FOUFELLE F., SCOTTO C., DAUCA M., WAHLI W.: Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366, 1996.
6. BUCHANAN T.A., MEEHAN W.P., JENG Y.Y., YANG D., CHAN T.M., NADLER J.L., SCOTT S., RUDE R.K., HSUEH W.A.: Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest. 96: 354-360, 1995.
7. BURANT C.F., SREENAN S., HIRANO K., TAI T.A.C., LOHMILLER J., LUKENS J., DAVIDSON N.O., ROSS S., GRAVES R.A.: Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100: 2900-2908, 1997.
8. CAMP HS, TAFURI S.R.: Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J. Biol. Chem. 272: 10811-10816, 1997.
9. CASTLE C.K., COLCA J.R., MELCHOR G.W.: Lipoprotein profile characterization of the KKA mouse, a rodent model of of type II diabetes, before and after treatment with insulin-sensitizing agent pioglitazone. Arterioscler. Thromb. 13: 307-309, 1992.
10. CAVAGHAN M.K., EHRMANN D.A., BYRNE M.M., POLONSKY K.S.: Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J. Clin. Invest. 100: 530-537, 1997.
11. CHANG A.Y., WYSE B.M., GILCHRIST B.J., PETERSON T., DIANI A.R.: Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 32: 830-838, 1983.
12. 1a antagonist and troglitazone. J. Hypertens. 14: 1325-1330, 1996.
13. CIARALDI T.P., GILMORE A., OLEFSKY J., GOLDBERG M., HEIDENREICH K.A.: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39: 1056-1062, 1990.
14. COMINACINI L., GARBIN U., PASTORINO A.M., CAMPAGNOLA M., FRATTA-PASINI A., DAVOLI A.: Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 40: 165-172, 1997.
15. DAVIS D.J.: The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268: 14553-14556, 1993.
16. DE VOS P., LEFEBVRE A.M., MILLER S.G., GUERRE-MILLO M., WONG K., SALADIN R., HAMANN L.G., STAELS B., BRIGGS M.R.: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J. Clin. Invest. 98: 1004-1009, 1996.
17. DUBEY R.K., ZHANG H.Y., REDDY S.R., BOEGEHOLD M.A., KOTCHEN T.A.: Pioglitazon attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. 265: R726-R732, 1993.
18. DUDLEY D.T., PANG L., DECKER S.J., BRIDGES A.J., SALTIEL A.R.: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92: 7686-7689, 1995.
19. DUNAIF A., SCOTT D., FINEGOOD D., QUINTANA B., WHITCOMB R.: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81: 3299-3306, 1996.
20. EHRMANN D.A., SCHNEIDER D.J., SOBEL B.E., CAVAGHAN M.K., IMPERIAL J., ROSENFIELD R.L., POLONSKY K.S.: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82: 2108-2116, 1997.
21. FREDERICH R.C., LOLLMANN B., HAMANN A., NAPOLITANO-ROSEN A., KAHN B.B., LOWELL B.B.: Expression of ob mRNA and its encoded protein in rodents. Impact on nutrition and obesity. J. Clin. Invest. 96: 1658-1663, 1995.
22. FUJITA T., SUGIYAMA Y., TAKETOMI S., SOHDA T., KAWAMATSU Y., IWATSUKA H., SUZUOKI Z.: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32: 804-810, 1983.
23. FUJIWARA T., YOSHIOKA S., YOSHIOKA T., USHIYAMA I., HORIKOSHI H.: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1849-1888, 1988.
24. FULGENCIO J.P., KOHL C., GIRARD J., PEGORIER J.P.: Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rat. Diabetes 11: 1556-1562 1996.
25. GHAZZI M.N, PEREZ J.E., ANTONUCCI T.K., DRISCOLL J.H., HUANG S.M., FAJA B.W., WHITCOMB R.W., THE TROGLITAZON STUDY GROUP: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46: 433-439, 1997.
26. GIMBLE J.M., ROBINSON C.E., WU X., KELLY K.A., RODRIGUEZ B.R., KLIEWER S.A., LEHMANN J.M., MORRIS D.C.: Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol. Pharmacol. 50: 1087-1094, 1996.
27. GRAF K., XI X.P., HSUEH W.A., LAW R.E.: Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett. 400: 119-121, 1997.
28. HAYAKAWA T., SHIRAKI T., MORIMOTO T., SHII K., IKEDA H.: Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem. Biophys. Res. Commun. 223: 439-444, 1996.
29. HOFMANN C., LORENZ K., COLCA J.R.: Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitaton. Endocrinology 129: 1915-1925, 1991.
30. HOTAMISLIGIL G.S., SHARGILL N.S., SPIEGELMAN B.M.: Adipose expression of tumor necrosis factor alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993.
31. HOTAMISLIGIL G.S., MURRAY D.L., CHOY L.N., SPIEGELMAN B.M.: Tumor necrosis factor alpha inhibits signaling from insulin receptor. Proc. Natl. Acad. Sci. USA 91: 4854-4858, 1995.
32. IWAMOTO Y., KOSAKA K., KUZUYA T., AKANUMA Y., SHIGETA Y., KANEKO T.: Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet. Med. 13: 365-370, 1996a.
33. IWAMOTO Y., KOSAKA K., KUZUYA T., AKANUMA Y., SHIGETA Y., KANEKO T.: Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19: 151-156, 1996b.
34. IZUMINO K., SAKAMAKI H., ISHIBASHI M., TAKINO H., YAMASAKI H., YAMAGUCHI Y., CHIKUBA N., MATSUMOTO K., AKAZAWA S.: Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. J. Clin. Endocrinol. Metab. 82: 2391-2395, 1997.
35. KATAYAMA S., ABE M., KASHIWABARA H., KOSEGAWA I., ISHII J.: Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. CS-045 does not lower blood pressure despite improvement of insulin resistance. Hypertension 23: 1071-1074, 1994.
36. KAUMI T., HIRANO T., ODAKA H., EBARA T A.N., HOZUMI T., ISHIDA Y.: VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone. Diabetes 45: 806-811, 1996.
37. KEMNITZ J.W., ELSON D.F., ROECKER E.B., BAUM S.T., BERGMAN R.N., MEGLASSON M.D.: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 43: 204-211, 1994.
38. KERN P.A., SAGHIZADEH M., ONG J.M., BOSH R.J., DEEM R., SIMSOLO R.B.: The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95: 2111-2119, 1995.
39. KOTCHEN T.A., ZHANG H.Y., REDDY S., HOFFMANN R.G.: Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am. J. Physiol. 270: R660-R666, 1996.
40. KUMAR S., BOULTON A.J., BECK-NIELSEN H., BERTHEZENE F., MUGGEO M., PERSSON B.: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 39: 701-709, 1996.
41. KUREBAYASHI S., HIROSE T., MIYASHITA Y., KASAYAMA S., KISHIMOTO T.: Thiazolidinediones downregulate stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes. Diabetes 46: 2115-2118, 1997.
42. LAW R.E., MEEHAN W.P., XI X.P., GRAF K., WUTHRICH D.A., COATS W., FAXON D., HSUEH W.A.: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98: 1897-1905, 1996.
43. LEE M.-K., OLEFSKY J.M.: Acute effects of troglitazone on in vivo action in normal rats. Metabolism 44: 1166-1169, 1995.
44. LEE M.-K., MILES P.D., KHOURSHEED M., GAO K.M., MOOSSA A.R., OLEFSKY J.M.: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43: 1435-1439, 1994.
45. LEHMAN J., MOORE L.B., SMITH-OLIVER T.A., WILKINSON W.O., WILLSON T.M., KLIEWER S.A.: An antidiabetic thiazolidine is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol Chem. 270: 12953-12956, 1995.
46. MAEGAWA H., TACHIKAWA-IDE R., UGI S., IWANISHI M., EGAWA K., IKKAWA R., SHIGETA Y., KASHIWAGI A.: Pioglitazone ameliorates high glucose induced desensitization of insulin receptor kinase in Rat 1 fibroblasts in culture. Biochem. Biophys. Res. Commun. 197: 1078-1082, 1993.
47. MASUDA K., OKAMOTO Y., TSUURA Y., KATO S., MIURA T., TSUDA K., HORIKOHI H., ISHIDA H., SEINO Y.: Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38: 24-30, 1995.
48. MILES P.D.G., ROMEO O.M., HIGO K., COHEN A., RAFAAT K., OLEFSKY J.M.: TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46: 1678-1683, 1997.
49. MURANO K., INOUE Y., EMOTO M., KAKU K., KANEKO T.: CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes. Eur. J. Pharmacol. 254: 257-262, 1994.
50. NADLER J., SCOTT S.: Evidence that pioglitazone increases intracellular free magnesium concentration in freshly isolated rat adipocytes. Biochem. Biophys. Res. Commun. 202: 416-421, 1994.
51. NAGASAKA Y., KAKU K., NAKAMURA K., KANEKO T.: The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem. Pharmacol. 50: 1109-1111, 1995.
52. NOGUCHI N., SAKAI H., KATO Y., TSUCHIYA J., YAMAMOTO Y., NIKI E.: Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 123: 227-234, 1996.
53. NOLAN J.J., LUDVIK B., BEERDSEN P., JOYCE M., OLEFSKY J.: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331: 1188-1193, 1994.
54. NOLAN J.J., OLEFSKY J.M., NYCE M.R., CONSIDINE R.V., CARO J.F.: Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes 45: 1276-1278, 1996.
55. OGIHARA T., RAKUGI H., IKEGAMI H., MIKAMI H., MASUO K.: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 8: 316-320, 1995.
56. OHSUMI J., SAKAKIBARA S., YAMAGUCHI J., MIYADAI K., YOSHIOKA S., FUJIWARA T.: Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 135: 2279-2282, 1994.
57. O'ROURKE C.M., DAVIS J.A., SALTIEL A.R., CORNICELLI J.A.: Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism 46: 192-198, 1997.
58. PERALDI P., XU M., SPIEGELMAN B.M.: Thiazolidines block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J. Clin. Invest. 100: 1863-1869, 1997.
59. PERSHADSINGH H.A., SZOLLOSI J., BENSON S., HYUN W.C., FEUERSTEIN B.G., KURTZ T.W.: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 21: 1020-1023, 1993.
60. REN J., DOMINGUEZ L.J., SOWERS J.R., DAVIDOFF A.J.: Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes 45: 1822-1825, 1996.
61. SAKU K., ZHANG B., OHTA T., ARAKAWA K.: Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am. J. Hypertens. 10: 1027-1033, 1997.
62. SALTIEL A.R., OLEFSKY J.M.: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669, 1996.
63. SANDOUK T., REDA D., HOFMANN C.: The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology 133: 352-359, 1993.
64. SANDOUK T., REDA D., HOFMANN C.: Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am. J. Physiol. 264: C1600-C1608, 1993.
65. SCHOONJANS K., STAELS B., AUWERX J.: Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrate and fatty acids on gene expression. J. Lipid Res. 37: 907-925, 1996.
66. SHIMABUKURO M., HIGA S., SHINZATO T., NAGAMINE F., KOMIYA I., TAKASU N.: Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 45: 1168-1173, 1996.
67. SIVITZ W.I., WALSH S.A., MORGAN D.A., THOMAS M.J., HAYNES W.G.: Effects of leptin in insulin sensitivity in normal rats. Endocrinology 138: 3395-3401, 1997.
68. SIZER K.M., SMITH C.L., JACOB C.S., SWANSON M.L., BLEASDALE J.E.: Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism. Mol. Cell. Endocrinol. 103: 1-12, 1994.
69. 2+ currents and not endothelial nitric oxide production. Diabetes 46: 659-664, 1997.
70. SPECTOR A.A., YOREK M.A.: Membrane lipid composition and cellular function. J. Lipid Res. 26: 1015-1035, 1985.
71. SREENAN S., STURIS J., PUGH W., BURANT C.F., POLONSKY K.S.: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am. J. Physiol. 271: E742-E747, 1996.
72. SZALKOWSKI D., WHITE-CARRINGTON S., BERGER J., ZHANG B.: Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136: 1474-1481, 1995.
73. TAFURI S.R.: Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology 137: 4706-4712, 1996.
74. TAKINO H., OKUNO S., UOTANI S., YANO M., MATSUMOTO K., KAWASAKI E.: Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome. Diabetes Res. Clin. Pract. 24: 167-172, 1994.
75. TEBOUL L., GAILLARD D., STACCINI L., INADERA H., AMRI E.Z., GRIMALDI P.A.: Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J. Biol. Chem. 270:28183-28187, 1995.
76. UCHIDA A., NAKATA T., HATTA T., KIYAMA M., KAWA T., MORIMOTO S, MIKI S, MORIGUCHI J., NAKAMURA K., FUJITA H., ITOH H., SASAKI S., TAKEDA K., NAKAGAWA M.: Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. Life Sci. 61: 455-464, 1997.
77. VAN DER POLL T., ROMIJN J.A., ENDERT E., BORN J.J., BULLER H.R., SAUERWEIN H.P.: Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am. J. Physiol. 261: E457-E465, 1991.
78. WEIGLE D.S., BUKOWSKI T.R., FOSTER D.C., HOLDERMAN S., KRAMER J.M., LASSER G., LOFTONDAY C.E., PRUNKARD D.E., RAYMOND C., KUIPER J.L.: Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J. Clin. Invest. 96: 2065-2070, 1995.
79. YOSHIMOTO T., NARUSE M., NISHIKAWA M., NARUSE K., TANABE A., SEKI T.: Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am. J. Physiol. 272: E989-E996, 1997.
80. YOSHIOKA S., NISHINO H., SHIRAKI T., IKEDA K., KOIKE H., OKUNO A., WADA M., FUJIWARA T., HORIKOSHI H.: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42: 75-80, 1993.
81. ZHANG F., SOWERS J.R., RAM J.L., STANDLEY P.R., PEULER J.D.: Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24: 170-175, 1994a.
82. ZHANG H.Y., REDDY S.R., KOTCHEN T.A.: Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 24: 106-110, 1994b.
83. ZHANG Y., PROENCA R., MAFFEI M., BARONE M., LEOPOLD L., FRIEDMAN J.M.: Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994c.